# Diabetes – Non-Insulin

This is a subcategory of Endocrine Agents.

## Formulary

### Preferred

| Preferred                               | Generic Name | Quantity | Time (Days) |
| :-------------------------------------- | :----------- | :------: | :---------: |
| Acarbose <sup>QL</sup>                                |              |          |             |
| Actoplus Met XR                         |              |          |             |
| Byetta                                  |              |          |             |
| Farxiga                                 |              |          |             |
| Glimepiride <sup>QL</sup>                             |              |          |             |
| Glipizide <sup>QL</sup>                               |              |          |             |
| Glipizide / Metformin <sup>QL</sup>                     |              |          |             |
| Glyburide <sup>QL</sup>                               |              |          |             |
| Glyburide / Metformin <sup>QL</sup>                     |              |          |             |
| Invokamet                               |              |          |             |
| Invokana                                |              |          |             |
| Janumet                                 |              |          |             |
| Janumet XR                              |              |          |             |
| Januvia                                 |              |          |             |
| Jardiance                               |              |          |             |
| Jentadueto                              |              |          |             |
| Metformin IR <sup>QL</sup>                               |              |          |             |
| Metformin ER <sup>QL</sup> (Generic of Glucophage XR) |              |          |             |
| Miglitol                                |              |          |             |
| Nateglinide <sup>QL</sup>                             |              |          |             |
| Pioglitazone <sup>QL</sup>                            |              |          |             |
| Pioglitazone / Metformin <sup>QL</sup>                 |              |          |             |
| Repaglinide                             |              |          |             |
| Repaglinide / Metformin                   |              |          |             |
| Synjardy                                |              |          |             |
| Tradjenta                               |              |          |             |
| Trulicity <sup>QL</sup>                               |              |          |             |
| Victoza <sup>QL</sup>                                |              |          |             |

### Non-Preferred

| Non-Preferred                      | Generic Name | Quantity | Time (Days) |
| :--------------------------------- | :----------- | :------: | :---------: |
| Adlyxin                            |              |          |             |
| Alogliptin                         |              |          |             |
| Alogliptin / Metformin               |              |          |             |
| Bydureon Bcise                     |              |          |             |
| Glimepiride / Pioglitazone           |              |          |             |
| Glucophage                         |              |          |             |
| Glyxambi                           |              |          |             |
| Invokamet XR                       |              |          |             |
| Jentadueto XR                      |              |          |             |
| Kombiglyze XR                      |              |          |             |
| Metformin ER <sup>QL</sup> (Generic of Fortamet) |              |          |             |
| Metformin Sol                      |              |          |             |
| Onglyza                            |              |          |             |
| Ozempic                            |              |          |             |
| Pioglitazone / Alogliptin            |              |          |             |
| Qtern                              |              |          |             |
| Rybelsus                           |              |          |             |
| Segluromet                         |              |          |             |
| Soliqua                            |              |          |             |
| Steglatro                          |              |          |             |
| Steglujan                          |              |          |             |
| Symlinpen                          |              |          |             |
| Synjardy XR                        |              |          |             |
| Trijardy XR                        |              |          |             |
| Xigduo XR                          |              |          |             |
| Xultophy                           |              |          |             |

## Length of Authorizations

365 Days

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **120 days** with at least **three preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Oral and Injectable Combination Drugs

Additional Oral and Injectable Combination Drugs Criteria

- Must have had a trial of at least **120 days** with the individual drugs **OR** must provide
documentation of medical necessity beyond convenience for patient’s inability to use
the individual drugs

## Additional Information

- An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen with documented adherence and appropriate dose escalation.
- Requests may be authorized for patients with a condition that is difficult to control (i.e., prone to ketoacidosis, hypoglycemia)
- For non-preferred drugs that have preferred drugs in the same drug class: must provide documentation that there was at least one inadequate clinical response with a drug in same drug class

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=54)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=21)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
